Canaccord Genuity Maintains Buy on Tenaya Therapeutics, Lowers Price Target to $17
Portfolio Pulse from jenniferd'souza@benzinga.com
Canaccord Genuity analyst Whitney Ijem maintains a Buy rating on Tenaya Therapeutics (NASDAQ:TNYA) but lowers the price target from $18 to $17.
August 11, 2023 | 11:53 am
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Canaccord Genuity maintains a Buy rating on Tenaya Therapeutics but lowers the price target from $18 to $17.
The news is directly related to Tenaya Therapeutics. While the maintained Buy rating is positive, the lowered price target might have a neutral to slightly negative impact on the stock's short-term performance.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100